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Objective: This study analyzes a single institution experience with minimally invasive mitral valve repair and
evaluates long-term surgical outcomes of morbidity, mortality, and rates of reoperation. Late follow-up of mitral
regurgitation and left ventricular function were also assessed.
Methods: Between August 1996 and October 2007, minimally invasive mitral valve repair was performed in 713
patients (mean follow-up 5.7 years). Excluding 6 repairs with robotic assistance, an perspective analysis of the
remaining 707 patients was carried forth. Mean age was 57  13 years. Mean preoperative ejection fraction
was 60%  10%. Surgical access was through a lower ministernotomy (74%), right parasternal incision
(24%), right thoracotomy (1.4%), or upper ministernotomy (0.7%). Exposure of the mitral valve was through
the left atrium in 58% of the cases and transeptal in 42%. A ring annuloplasty was incorporated into 680
(96%) of 707 repairs. The Kaplan–Meier and Student t test for paired samples were used for statistical analysis.
Results: There were 3 (0.4%) operative deaths. Perioperative morbidity included new-onset atrial fibrillation
(20%), reoperation for bleeding (2%), stroke (1.9%), permanent pacemaker implantation (1.7%), deep sternal
wound infection (0.7%), and aortic dissection (0.4%). Median hospital stay was 5 days. Only 31% of patients
required blood transfusion during the hospital course. There were 49 (6.9%) late deaths and 34 (4.8%) failed
repairs necessitating reoperation. At 11.2 years, survival was 83% (95% confidence intervals, 76.5–88.1); free-
dom from reoperation was 92% (95% confidence intervals, 86.2–94.9). Nine (1.3%) patients were lost to follow-
up. A total of 2369 patient-years of echocardiography time were obtained in 544 patients (mean 4.36 years, range
0.47–11.09). Mean grade of mitral regurgitation decreased from 3.80 to 1.42 (P< .0001) Mean left ventricular
ejection fraction decreased from 60.7% to 56.3% (P< .0001). Combined risk of death, reoperation, and recur-
rence of moderately severe to severe mitral regurgitation was 7.7% (43/555).
Conclusion: Minimally invasive mitral valve repair is safe, with low perioperative morbidity, low rates of recur-
rent mitral regurgitation, and low rates of reoperation and death at late follow-up.Earn CME credits at
http://cme.ctsnetjournals.org
Minimally invasive mitral valve surgery has been proven
a feasible alternative to the conventional full sternotomy ap-
proach with low perioperative morbidity and short-term
mortality.1,2 Efforts to minimize surgical trauma, hasten pa-
tient recovery, increase patient satisfaction, and reduce cost,
without compromise to surgical repair or replacement tech-
niques, continue to be the rationale for minimally invasive
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year experience with minimally invasive mitral valve repair
(MVP), assessing morbidity, mortality, rates of reoperation,
and repair durability via follow-up echocardiography, in an
effort to better quantify long-term outcomes with these tech-
niques.
PATIENTS AND METHODS
From August 1996 to October 2007, 2181 patients underwent isolated
mitral valve surgery (defined as mitral valve surgery without coronary artery
bypass grafting). There were 1512 MVPs and 669 mitral valve replacements
(MVRs). A minimally invasive approach was used in 780 (36%) patients.
Minimally invasive MVR and MVP were performed in 67 (67/669, 10%)
and 713 (713/1512, 47%) patients, respectively. Patient selection was pred-
icated by surgeon preference. Absolute contraindications to undergoing
minimally invasive mitral valve surgery were surgically significant coro-
nary artery disease, atrial fibrillation deemed amenable to surgical maze
treatment, chest wall deformities, and morbid obesity. Excluding 6 patients
who had MVP with robotic assistance, a cohort of 707 patients underwent
isolated minimally invasive MVP and is the basis of this review.
After receiving approval from the Institutional Review Board of Partners
Healthcare, we reviewed prospectively entered data from the database of the
Brigham Cardiac Valve Center, collecting all prevalent preoperative, intra-
operative, and postoperative outcome data for the cohort of interest. In
addition, all operative notes and discharge summaries were reviewed to
cross-reference the database, input data that was missing from the database,
and to collect supplementary surgical procedural data. Data extraction fromgery c January 2009
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CI ¼ confidence intervals
MR ¼ mitral regurgitation
MVP ¼ mitral valve repair
MVR ¼ mitral valve replacement
operative notes and discharge summaries was focused on key variables:
preoperative ejection fraction, grade of mitral regurgitation (MR), valve
pathology, reparative techniques, and intraoperative and postoperative
complications. Follow-up vital status was obtained from the US Social
Security Death Index.3 Long-term echocardiographic data (defined as  6
months) missing from the database were collected through direct contact
with cardiology and primary care offices. In the instance where the referring
cardiologist or primary care physician had lost contact with the patient,
patients were contacted directly.
The main end points of interest were perioperative complications, 30-
day mortality, recurrence of MR, reoperation rates, and overall survival. All
statistical data were analyzed with Stata 10.0 for Windows software (Stata
Corporation, College Stage, Tex). Statistical data were expressed as a per-
centage mean  1 standard deviation or via 95% confidence intervals
(CI). Survival analysis and time-to-event analysis for rates of reoperation
were assessed by the Kaplan–Meier method. Patient’s grade of residual or
recurrent MR and left ventricular ejection fraction were compared with
baseline preoperative measurements by the Student t test for paired samples.
Patient characteristics at baseline are listed in Table 1. The mean age was
57 years. More than 60% of patients were male. Mean preoperative left ven-
tricular ejection fraction was 60% and mean New York Heart Association
functional class was 2.0. Mitral valve pathology was regurgitant in 691
(98%) patients and mixed (regurgitant and stenotic) in 16 (2%) patients.
Myxomatous degenerative disease was the predominant pathologic condi-
tion, witnessed in 88% of the cohort. Other conditions such as rheumatic,
endocarditic, ischemic, calcific, and dilatative cardiomyopathy were also
treated. Preoperative chronic atrial fibrillation was noted in 143 (20%)
patients.
Surgical access for minimally invasive MVP has been modified over
time at our institution, with the current approach of lower ministernotomy
being the standard since late 2001. These techniques have previously
been described.1,4 In brief, a 6- to 8-cm skin incision over the lower sternum
was performed distal to the manubriosternal junction and extending distal to
a level 2 fingerbreadths proximal to the xiphoid. With a sternal saw, a hemi-
sternotomy was performed from the base of the xiphoid process to the sec-
ond intercostoal space. The hemisternotomy was then extended to the right
second intercostal space with an oscillating saw. Cardiopulmonary bypass
was initiated predominantly through direct cannulation of the ascending
aorta and percutaneous cannulation of the inferior vena cava via the femoral
vein assisted by transesophageal echocardiography. Undersized (16F–24F)
vacuum-assisted cannulas improved surgical exposure while maintaining
venous drainage. Drainage of the superior vena cava was usually by small
cannula insertion directly into the superior vena cava. Cardioplegia was
used in all patients; 620 had antegrade and 87 had both antegrade and
retrograde routes. With improved instrumentation, from November 2001
onward, a left atrial incision via Sondergaard’s groove5 became the pre-
ferred approach for mitral valve exposure. The right atrial transseptal ap-
proach was used only if predicated by tricuspid valve disease, atrial septal
defect, or an oversized right atrium. Before November 2001 the right atrial
transseptal approach was used almost exclusively. Intracardiac air was re-
moved by cardiac filling and active aortic root suction under transesopha-
geal echocardiographic guidance. A complete list of all operative
techniques used is listed in Table 2.
MVP techniques are listed in Table 3. Posterior leaflet resection and slid-
ing or modified sliding valvuloplasty with placement of an annuloplastyThe Journal of Thoracic and Cring was used in the majority of patients. Anterior leaflet pathology was
implicated in 184 (26%) of the reparative procedures. The most frequently
inserted annuloplasty device was the Cosgrove–Edwards ring (Edwards
Lifesciences, Irvine, Calif). Twenty-seven patients did not receive an annu-
loplasty ring because there was no perceived annular dilatation, the annulus
was too heavily calcified, severe systolic anterior motion on insertion of the
ring prompted its removal, or because of concern about recent acute endo-
carditis.
TABLE 1. Preoperative baseline characteristics (n ¼ 707)
Age (y), SD, range 57  13 17–89
Male, n, (%) 429 61%
NYHA functional class, mean, SD 2.0  0.8
Class I/II, n, (%) 540 76%
Class III/IV, n, (%) 167 24%
Ejection fraction (%),mean, SD 60.4  10
Mitral valve pathology, n, (%)
MR 691 98%
MR and MS 16 2%
Mitral valve disease, n, (%)
Myxomatous 622 88%
Anterior leaflet prolapse 33 5%
Bileaflet prolapse 151 24%
Posterior leaflet prolapse 438 70%
Dilatative cardiomyopathy 27 3.8%
Rheumatic 25 3.5%
Endocarditis 22 3.1%
Ischemic 4 0.6%
Calcific/degenerative 4 0.6%
Other 3 0.4%
MR grade (0–4) mean, SD 3.80  0.42
Preoperative AF, n, (%) 143 20%
SD, Standard deviation; NYHA, New York Heart Association; MR, mitral regurgita-
tion; MS, mitral stenosis; AF, atrial fibrillation.
TABLE 2. Operative techniques (n ¼ 707)
N %
Incision
Lower ministernotomy 524 74%
Right parasternal 168 24%
Right thoracotomy 10 1.4%
Upper ministernotomy 5 0.7%
Surgical approach
Left atrium 407 58%
Right atrium 300 42%
Cannulation for cardiopulmonary bypass
Arterial cannulation
Aorta 577 82%
Femoral 130 18%
Venous cannulation
Right atrium–bicaval 407 58%
Femoral vein/SVC or IVC 300 42%
Cardioplegia
Antegrade only 620 88%
Antegrade and retrograde 87 12%
Operative duration (min), SD, range
Mean aortic crossclamp 85  30 28–274
Mean cardiopulmonary bypass 123  39 48–318
SVC, Superior vena cava; IVC, inferior vena cava; SD, standard deviation.ardiovascular Surgery c Volume 137, Number 1 71
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Operative results are listed in Table 4. There were 3 oper-
ative deaths (<30 days or same hospital admission) in 707
patients (0.4%). Blood transfusions were required during
the hospitalization of 220 (31%) patients. New-onset atrial
fibrillation occurred in 115 (20%) of the 564 patients admit-
ted in sinus rhythm. Reoperation for bleeding occurred in 14
(2%) patients. Twelve (1.7%) had a cerebral vascular acci-
dent documented by computed tomographic scan. A perma-
nent pacemaker for conjunctional rhythm or complete heart
block was required in an additional 12 patients. Five (0.7%)
patients had a myocardial infarction. Wound complications
consisted of 5 (0.7%) deep sternal infections and 2 (0.3%)
dehisced parasternal incisions necessitating reoperation
from early in the series. There were 10 (2.3%; 5/130
arterial, 5/300 venous) femoral cannulation–related injuries
in 8 patients necessitating surgical revision. In addition, 3
(0.4%) patients from our early experience incurred local
ascending aortic dissections as a result of cardioplegia
needle placement. Surgical repair of the aorta was accom-
plished in each case through the original incision. Finally,
TABLE 3. Surgical repair techniques (n ¼ 707)
N %
Mitral valve repair
Posterior leaflet resection or modified
resection and sliding annuloplasty
550 78%
Commisuroplasty 124 18%
Edge-to-edge stitch 70 10%
Imbrication suture 49 7%
Chordoplasty 43 6%
Annuloplasty only 37 5%
Cleft closure 28 4%
Commisurotomy 15 2%
Decalcification 13 2%
Anterior leaflet resection 8 1%
Compression suture 3 0.4%
Valve debridement 3 0.4%
Ring annuloplasty
Annuloplasty ring 680 96%
Cosgrove–Edwards ring* 631 89%
Carpentier–Edwards Physio ring* 29 4%
Carbodmedics Annuloflex ringy 10 1.4%
Carpentier–Edwards Classic ring* 8 1.1%
Bolling GeoForm ring* 1 0.1%
Future Medtronic ringz 1 0.1%
No annuloplasty 27 3.8%
Secondary procedures
TVP 22 3.1%
ASD 12 1.7%
Ascending aorta repair 2 0.3%
Aortic valve repair 1 0.1%
Carotid endarterectomy 1 0.1%
TVP, Tricuspid valve repair; ASD, atrial septal defect. *Edwards Lifesciences, Irvine,
Calif. ySulzer CarboMedics, Inc, Austin, Tex. zMedtronic, Inc, Minneapolis, Minn.72 The Journal of Thoracic and Cardiovascular Sur1 patient’s course was complicated by biventricular failure
and cardiogenic shock resulting in the implantation of a bi-
ventricular assist device and eventual heart transplantation.
Median length of hospital stay was 5 days. Only 49 (7%)
patients required convalescence at a rehabilitation facility
on hospital discharge. All other patients were discharged
directly home.
Late Follow-up
Clinical follow-up was achieved in 698 (98.7%) patients
with a mean follow-up of 68.2 months (range 0.5–135)
(Table 5). Nine patients residing in foreign countries were
lost to follow-up. There were 49 (7%) late deaths, and the
overall survival at 11.2 years was 83% (95% CI,
76.4–88.0) (Figure 1). The cause of death could only be de-
termined for 13 (27%) patients, of which 7 were cardiac re-
lated. Freedom from reoperation at 11.2 years was 92%
(95%CI, 86.2&ndash94.9) (Figure 2). Thirty-four (4.8%)
patients had a failed MVP requiring a second operation.
The cause of failed repair was myxomatous in 24 (24/622,
3.9%) patients, rheumatic in 5 (5/25, 20%), prior endocar-
ditis in 4 (4/22, 18%), and ischemic in 1 (1/4, 25%) patient.
Anterior leaflet involvement (12/34, 35%) or an inability
to accommodate annuloplasty ring insertion (9/34, 26%)
was involved in 65% of the failed repairs (Table 5). In
addition to 9 patients having had a repair without an annulo-
plasty ring, other indications for reoperation included the
TABLE 4. Perioperative morbidity and mortality (n ¼ 707)
N %
Thirty-day mortality 3 0.4%
Cardiac complications
New atrial fibrillation 115/564 20%
Permanent pacemaker 12 1.7%
Myocardial infarction 5 0.7%
Intra-aortic balloon pump required 4 0.6%
Other operative morbidity
Pleural effusion drained 18 2.5%
Reoperation for bleeding 14 2.0%
CVA documented on CT 12 1.7%
Pericardial effusion requiring drainage 8 1.1%
Wound complications
Deep sternal wound infections 5 0.7%
Dehiscence 2 0.3%
Vascular complications
Femoral vessel injury 10/430 2.3%
Arterial 5/130 3.8%
Venous 5/300 1.7%
Deep vein thrombosis/pulmonary embolism 4 0.6%
Ascending aortic dissection 3 0.4%
Pseudoaneurysm 2 0.3%
Homologous blood transfusion 220 31%
Hospital length of stay (d), median, mean, SD 5 6.4  4.8
Transfer to rehabilitation center 49 6.9%
CVA, Cerebral vascular accident; CT, computed tomography; SD, standard deviation.gery c January 2009
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chordae (n ¼ 2), ring dehiscence (n ¼ 1), leaflet perforation
(n ¼ 2), mitral stenosis (n ¼ 2), progressive Libman–Sacks
endocarditis (n ¼ 1), progressive ischemic cardiomyopathy
(n ¼ 1), scarred fixation of the posterior leaflet (n ¼ 3), and
a failed complicated anterior repair that necessitated multi-
ple artificial chordae and two anterior leaflet resections
(n ¼ 1). The 8 remaining patients underwent reoperation
TABLE 5. Late clinical follow-up
N %
Clinical follow-up (n ¼ 707)
Follow-up time (mo), mean, range 68.2 0.5–135
Late deaths 49/707 7%
Failed repair 34/707 4.8% 1.7%
Anterior or bileaflet (n ¼ 12) 12/707 17%
Ruptured chordae 2/12 17%
Loosened artificial chordae 2/12 17%
Mitral stenosis 1/12 8%
Leaflet perforation 1/12 8%
Ring dehiscence 1/12 8%
Complex repair failure 1/12 8%
Repaired at other institution 4/12 33%
No ring (n ¼ 9) 9/707 1.3%
Potential for systolic anterior motion 4/9 44%
No annular dilatation 2/9 22%
Excessive calcification 1/9 11%
Subacute endocarditis 1/9 11%
Rheumatic 1/9 11%
Posterior (n ¼ 10) 10/707 1.4%
Extensively scarred/fixated leaflet 3/10 30%
New anterior chordal rupture 2/10 20%
Leaflet perforation 1/10 10%
Libman–Sacks endocarditis 1/10 10%
Repaired at other institution 3/10 30%
Other (n ¼ 3) 3/707 0.4%
Rheumatic 2/3 67%
Ischemic 1/3 33%
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FIGURE 1. Actuarial survival estimates.The Journal of Thoracic andat other institutions. Rerepair was possible in 7 patients
with 27 patients undergoing MVR. Other reoperations
included aortic valve replacement (n ¼ 2) and heart trans-
plantation for end-stage dilated cardiomyopathy (n ¼ 1).
With 6 months used to define minimum long-term follow-
up, 656 (92%) of 707 patients were eligible for late follow-up
echocardiographic assessment (Table 6). Criteria for exclu-
sion were early death, early reoperation, or less than 6 months
of follow-up time at the start of the study.
Late follow-up echocardiographic studies were obtained
in 544 (83%) of the 656 eligible patients for a total of
2369 patient-years. In the instance in which a patient under-
went a reoperation for a failed repair beyond 6 months and
the mitral valve was successfully rerepaired, only the echo-
cardiography report at the time of reoperation was used in
the analysis of recurrent MR. Reasons for not attaining
late echocardiographic studies in eligible patients were late
death (24 patients), foreign residence (9 patients), failure
to receive a follow-up echocardiogram at the referring center
(56 patients), or loss to follow-up (23 patients). Duration of
follow-up ranged from 5.6 to 133.2 months (mean 52.3 34
months). Long-term MR was reduced from a mean preoper-
ative grade of 3.80 (95% CI, 3.76–3.83) to 1.42 (95% CI,
1.34–1.51) (P< .0001). Mean preoperative left ventricular
ejection fraction decreased from 60.7% (95% CI, 59.8–
61.5) to 56.3% (95% CI, 55.5–57.0) (P< .0001) over the
same period. Over half (56%) of all patients had trace or
no MR at follow-up and 88% (475/544) had mild MR or
less. Ten patients had severe MR, 16 patients had moder-
ately severe MR, and 43 patients had moderate MR.
Of those patients with recurrent MR of high significance
(moderately severe to severe MR), only 6 patients (5 patients
with moderately severe MR, 1 patient with severe MR) have
yet to undergo reoperation. The combined risk of death, re-
operation, and recurrence of moderately severe to severe
MR was 7.7% (43/555).
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FIGURE 2. Actuarial event-free survival estimates. MVP, Mitral valve
repair.Cardiovascular Surgery c Volume 137, Number 1 73
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Mitral valve assessment Preoperative Postoperative P value
MR grade,* mean, 95% CI 3.80 (3.76–3.83) 1.43 (1.34–1.50) <.0001
None/trivial MR 0 101 (19%)
Trace MR 0 199 (37%) 88%
Mild MR 0 175 (32%)
Moderate MR 63 (12%) 43y (8%)
Moderate to severe MR 72 (13%) 88% 16z (3%)
Severe MR 406 (75%) 10{ (1.8%)
LVEF, mean, 95% CI 60.7% (59.8–61.5) 56.3% (55.5–57.0) <.0001
LVEF 30% 10 (1.8%) 14 (2.6%)
LVEF 31–39% 8 (1.5%) 9 (1.7%)
LVEF 40–49% 21 (4%) 42 (7.7%)
LVEF>50% 505 (93%) 479 (88%)
MR, Mitral regurgitation; LVEF, left ventricular ejection fraction; CI, confidence intervals. *Mitral regurgitation (MR) grading scheme: None/trivial ¼ 0 MR; trace ¼ 1+ MR;
mild ¼ 2+ MR; moderate ¼ 3+ MR; severe ¼ 4+ MR. y6/43 have had a reoperation. z11/16 have had a reoperation. {9/10 have had a reoperation.DISCUSSION
In this the second of what will likely be several revisits to
the outcomes from a large cohort of minimally invasive
MVP, the promising results from the initial review have con-
tinued to endure with time.1 Operative mortality is less than
0.5%, major morbidity has remained low, and rates of reop-
eration have decreased from 5.8% to 4.8%. Moreover, pre-
viously known risk factors for MVP failure, those being
anterior leaflet pathology6 and reparative procedures that
do not include the insertion of an annuloplasty ring,7,8
were expectantly reaffirmed. The incidence of reoperation
for anterior leaflet pathology continues to be 7% in this co-
hort. With respect to ring insertion, since the previous re-
view, which documented one fourth of reoperations to
occur in patients who did not have a ring annuloplasty inser-
tion, only 7 of 349 patients have undergone minimally inva-
sive MVP without incorporation of an annuloplasty ring.
Despite more than a 2-fold reduction in MVP performed
without an annuloplasty ring, one fourth of all reoperations
were still a result of surgical repairs performed without ring
insertion. To date, 33% of repairs without an annuloplasty
ring have required reoperation, despite achieving intraoper-
ative competence, re-emphasizing the key importance of
these devices for good long-term results.
Beyond revisiting clinical outcomes, efforts were made
to acquire echocardiographic data so as to assess in a more
objective manner the long-term durability of minimally
invasive MVP. MR was shown to have decreased from
a qualitative grade of 3.80 to 1.43, both a statistically and
clinically significant finding. Outcome studies have demon-
strated the benefits of mitral valve surgery for both symp-
tomatic9 and asymptomatic10 patients with organic MR.
Over 95% of this cohort had organic pathology, and the ma-
jority had preserved left ventricular function. To have sus-
tained what is a clear, clinically relevant improvement in
MR grade, in the face of low surgical complication rates,
over a duration of 2000 patient-years, lends further credence74 The Journal of Thoracic and Cardiovascular Surgto the importance of referring patients for MVP early in the
disease process.
The decrease in left ventricular ejection fraction from
60.7% to 56.3% was also a statistically significant finding
and is in keeping with previous reports from conventional
MVP.11 Still, contrary to the statistical findings for MR
grade at late follow-up, the statistical significance of the re-
duction in left ventricular ejection fraction from 61% to
56% does not correlate to an overt clinical significance
and can be interpreted to show modest preservation over
time.
Recurrent MR was identified to be moderately severe or
worse (3.5þ) in 4.8% of patients. Reports in the literature
on the recurrence of significant MR have a broad range, from
4.8% to 29%.12 Notably, between studies comparisons are
problematic. Dissimilarities in disease processes and echo-
cardiographic intraobserver variability render such compar-
isons fraught with confounding results and therefore
misleading.
The adoption of minimally invasive techniques at our
institution has resulted in long-term outcomes that appear
comparable with conventional sternotomy procedures.
These outcomes should be given clear recognition as we
move forward with percutaneous valve technology.13 Al-
though advancements in percutaneous valve therapy are to
be encouraged in an effort to improve patient care, percuta-
neous procedures must be held accountable and to the same
standards regarding patient outcomes if they are ever to be
seriously considered beyond the most select of patient pop-
ulations. In addition to these long-term results, although it
was an unadjusted analysis, we4 have previously demon-
strated reductions in cardiopulmonary bypass time, aortic
crossclamp time, and median length of hospital stay for min-
imally invasive MVP in comparison with conventional
MVP. Still, 606 (85%) of 713 minimally invasive MVPs
were performed by a single surgeon (L.H.C.), and this
accounts for 65% (606/930) of all isolated MVPs performedery c January 2009
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comes that continue to show promise, it is expected that min-
imally invasive techniques for MVP will disseminate further
and adoption at the Brigham will increase. Other centers
have also shown promising results with minimally invasive
approaches to MVP. Casselman and associates14 have
gained considerable expertise in endoscopic cardiac surgery,
publishing results on 226 patients in whom these techniques
were used for MVP. In a series in which 15% of patients had
anterior leaflet pathology and 7% had endocarditis, they re-
ported 1 (0.4%) early death and 3 conversions to sternot-
omy; freedom from reoperation at 4 years was 93.3% 
2.6%. Reviewing their complete endoscopic valve series
of 306 patients consisting of both aortic and mitral valve re-
pair and replacement procedures, 94.2% of patients stated
no procedural or minimal procedural pain and 99.3% were
extremely pleased with the cosmetic results. Chitwood and
Rodriguez15 have become synonymous with robotic cardiac
surgery and have performed more than 200 robotic mini-
mally invasive MVPs to date. Early death is 2% in this
cohort with no or trace MR via postoperative echocardiogra-
phy in 96.5% of patients. Independently, the surgical teams
of Umakanthan,16 Loulmet,17 and their associates have re-
cently reported on their early experience with minimally
invasive valve surgery through a right anterolateral mini-
thoracotomy in conjunction with hypothermic or induced
fibrillatory arrest to avoid aortic crossclamping and cardio-
plegic ischemia. Both groups have had success with this
approach, maintaining low perioperative morbidity and mor-
tality in the short term.
This review has certain limitations. The review is largely
retrospective and lacks a control group for appropriate com-
parisons. The inability to determine late cause of death in the
majority of patients and the inability to attain 100% late
echocardiographic assessment are additional weaknesses.
Despite these limitations, the strengths of this review are
quite conclusive. With near complete clinical follow-up in
more than 707 patients and late echocardiographic follow-
up in more than 540 patients, the results of this review are ro-
bust. This study reaffirms the notion that minimally invasive
surgery is an excellent intervention for mitral valve disease.The Journal of Thoracic andIn conclusion, minimally invasive MVP is safe, with low
perioperative morbidity, low rates of recurrent MR, and low
rates of reoperation and death at late follow-up.
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